
중남미 저분자량 헤파린 시장 예측(2028년) 심부정맥혈전증, 급성관상동맥증후군(ACS), 폐색전증 등] 및 최종 사용자(병원, 진료소, 외래 수술 센터 및 기타)
No. of Pages: 128 | Report Code: TIPRE00027115 | Category: Life Sciences
No. of Pages: 128 | Report Code: TIPRE00027115 | Category: Life Sciences
Â
의료관광으로 유명한 중남미 국가들은 최근 2년간 코로나19 사태로 부작용을 겪었다. 코로나19(COVID-19)의 두 번째 확산이 시작된 후 아르헨티나에서는 5,395,044명의 새로운 사례가 발생했습니다. 이에 따라 해당 지역은 2021년 2차 봉쇄를 앞두고 있었다. 2020년에는 무기한 사업 중단으로 시장 이해관계자들이 사업을 잃었다. SARS-2-CoV는 염증 반응 증가, 저산소증, 부동화 및 DIC로 인해 VTE 또는 동맥 질환에 기여할 수 있습니다. 중증 코로나19 환자의 경우 VTE 발생 위험이 더 높습니다. 지혈 변화 외에도 부동성, 전신 염증 상태, 기계적 환기 및 중앙 카테터는 혈전색전증의 위험을 증가시키는 반면, 식이 관련 및 간 변화는 응고 인자의 생성을 변화시킵니다. VTE에 대해 확인된 위험 요소에는 중환자실 입원, 높은 백혈구 수, 호중구/림프구 비율 및 D-이량체 값이 포함됩니다. 코로나19 팬데믹은 다양한 방식으로 혈전성 또는 혈전색전성 질환의 예방과 치료에 영향을 미칠 수 있습니다. 혈전 예방, 항응고에 대한 프로토콜과 응고 장애 및 출혈 관리를 위한 추가 고려 사항은 해당 지역의 최신 권장 사항에 따라 각 시설에서 구현되어야 합니다.
Â
< Strong>Â
Strategic insights for South and Central America Low Molecular Weight Heparin involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 202.69 Million |
Market Size by 2028 | US$ 303.39 Million |
Global CAGR (2021 - 2028) | 5.9% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 제품 유형
|
Regions and Countries Covered | 남미 및 중미
|
Market leaders and key company profiles |
The regional scope of South and Central America Low Molecular Weight Heparin refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The South and Central America Low Molecular Weight Heparin Market is valued at US$ 202.69 Million in 2021, it is projected to reach US$ 303.39 Million by 2028.
As per our report South and Central America Low Molecular Weight Heparin Market, the market size is valued at US$ 202.69 Million in 2021, projecting it to reach US$ 303.39 Million by 2028. This translates to a CAGR of approximately 5.9% during the forecast period.
The South and Central America Low Molecular Weight Heparin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Low Molecular Weight Heparin Market report:
The South and Central America Low Molecular Weight Heparin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Low Molecular Weight Heparin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Low Molecular Weight Heparin Market value chain can benefit from the information contained in a comprehensive market report.